ERBB2 and breast cancer: A randomized clinical trial of more than 2500 patients was conducted by Coombes in 2021 and recruited patients with epidermal growth factor-2 (HER-2)-negative early breast cancer, treated with adjuvant chemotherapy plus celecoxib, which was administered for 2 years, versus placebo.